Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Therapy for ARDS in COVID-19
NCT04366063Phase 3Unknown
- Sponsor
- Royan Institute
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of mesenchymal stem cells in acute respiratory distress syndrome (ARDS), sponsored by Royan Institute. Status: unknown.
02
Drugs
mesenchymal stem cells
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04366063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366063.